GlassScriptPhysician profile
Clifford E Medina
NPI 1477634129
$2,445.74
in general payments reported to CMS, 2019-2025
32 companies · $977 in 2025
The $977 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $59.21 · 2021: $101 · 2022: $108 · 2023: $180 · 2024: $875 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $322.44 | 2020-2025 | |
| Boston Scientific Corporation | $293.50 | 2024-2025 | Watchman Flx, General - Therapies |
| Amgen INC. | $289.37 | 2019-2025 | Repatha, Krystexxa, Evenity |
| Novo Nordisk INC | $249.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $157.91 | 2023-2025 | Shingrix, Arexvy |
| Pfizer INC. | $133.06 | 2024-2025 | |
| Scpharmaceuticals INC. | $117.87 | 2024-2025 | |
| Heartflow, INC. | $110.36 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $87.40 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $72.75 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.57 | 2019-2020 | |
| Viiv Healthcare Company | $61.78 | 2025 | Apretude |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.40 | 2024 | Lifevest |
| Lilly USA, LLC | $51.79 | 2024-2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $47.51 | 2023 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $41.89 | 2019-2025 | Lokelma |
| Lexicon Pharmaceuticals, INC. | $31.13 | 2024 | |
| Edwards Lifesciences Corporation | $30.50 | 2024 | |
| Exact Sciences Corporation | $24.17 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $23.48 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.15 | 2024 | Uptravi, Opsumit |
| Baxter Healthcare | $22.38 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $21.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.27 | 2021 | |
| Merck Sharp & Dohme LLC | $18.91 | 2020 | |
| Relievant Medsystems, INC. | $18.85 | 2021 | |
| Esperion Therapeutics, INC. | $16.92 | 2024 | Nexletol |
| Medicure Pharma INC. | $13.85 | 2025 | Zypitamag |
| Allergan, INC. | $11.71 | 2019 | |
| Radius Health, INC. | $10.98 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.